Who
Claire Mazumdar
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Bicara Therapeutics; Director, Relay Therapeutics.
In numbers
- Trades disclosed
- 101
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $6.4M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 Jun 2025
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Oct 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $280K10,000 at $27.98 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.79 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $280K10,000 at $27.98 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.79 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $283K9,972 at $28.42 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $83128 at $29.68 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.79 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $283K9,972 at $28.42 | filing |
| 10 Jul 2026filed 14 Jul 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $83128 at $29.68 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Code M | $57K15,000 at $3.79 | filing |
| 18 May 2026filed 20 May 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $240K12,022 at $19.96 | filing |
| 18 May 2026filed 20 May 2026 | BCAX Bicara TherapeuticsBiotechnology | SEC FORM 4 Sold | $61K2,978 at $20.35 | filing |
| 18 May 2026filed 20 May 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.